Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.26B | 10.10B | 9.38B | 9.94B | 8.69B |
| Gross Profit | 11.16B | 9.07B | 8.51B | 9.06B | 7.89B |
| EBITDA | 4.25B | 4.20B | 2.93B | 3.08B | 2.99B |
| Net Income | 4.37B | 3.28B | 2.58B | 2.71B | 2.57B |
Balance Sheet | |||||
| Total Assets | 31.66B | 33.04B | 30.00B | 27.16B | 20.79B |
| Cash, Cash Equivalents and Short-Term Investments | 23.39B | 24.86B | 21.63B | 18.94B | 13.73B |
| Total Debt | 117.89M | 4.30B | 4.38B | 3.83B | 92.75M |
| Total Liabilities | 2.98B | 7.24B | 7.35B | 7.13B | 2.92B |
| Stockholders Equity | 28.68B | 25.79B | 22.65B | 20.03B | 17.88B |
Cash Flow | |||||
| Free Cash Flow | 3.64B | 2.90B | 2.47B | 2.12B | 962.83M |
| Operating Cash Flow | 3.86B | 3.12B | 2.74B | 2.58B | 2.39B |
| Investing Cash Flow | -1.39B | 1.07B | -5.94B | -2.26B | -2.87B |
| Financing Cash Flow | -6.07B | -753.70M | -818.14M | 3.42B | -1.04B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Hansoh Pharmaceutical Group Company Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$185.25B | 38.97 | 16.09% | 1.10% | 19.29% | 31.35% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
| $5.69B | 9.75 | 7.22% | 2.49% | ― | ― | ||
| $4.21B | 12.02 | 14.56% | 0.56% | ― | ― | ||
| $8.72B | 12.84 | 6.22% | 1.96% | ― | ― | ||
| €3.54B | 7.96 | 6.98% | ― | ― | |||
78 Outperform | HK$33.72B | 13.48 | 15.61% | 2.74% | 10.59% | 31.83% |
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Pharmaceutical Group Company Limited held its Annual General Meeting on June 20, 2025, where all proposed resolutions were passed with significant support. Key decisions included the adoption of the company’s financial statements, approval of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. These resolutions reflect the company’s stable financial health and strategic plans for growth, potentially enhancing shareholder value and strengthening its market position.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced that its innovative drug, Aumolertinib Mesilate Tablets, has been approved by the UK’s Medicines and Healthcare Products Regulatory Agency for marketing. This approval marks a significant milestone for the company as it expands its market presence in the UK, offering treatment options for patients with specific mutations of non-small cell lung cancer. The approval is expected to enhance the company’s position in the pharmaceutical industry and provide new opportunities for growth.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has entered into a license agreement with Regeneron Pharmaceuticals, Inc., granting Regeneron an exclusive worldwide license to develop, manufacture, and commercialize the investigational drug HS-20094 outside of the Chinese Mainland, Hong Kong, and Macau. This agreement could potentially bring Hansoh up to $1.93 billion in milestone payments and double-digit royalties, enhancing its market position and leveraging its technology platforms. The agreement is seen as beneficial for Hansoh’s shareholders and aligns with the company’s strategic goals.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced that the National Medical Products Administration has accepted the third biologics license application for XINYUE (Inebilizumab Injection) for treating generalized myasthenia gravis in adult patients. This acceptance marks a significant step in expanding the treatment options for this condition, reinforcing Hansoh’s position in the pharmaceutical industry and potentially enhancing its market share and influence in the region.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed HS-20118 tablets have received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials for the treatment of moderate to severe plaque psoriasis, potentially enhancing its position in the pharmaceutical industry and offering new treatment options for patients.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed innovative drug, HS-10542 capsules, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to conduct clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria and immunoglobulin A nephropathy, potentially strengthening its position in the pharmaceutical industry and offering new treatment options for these conditions.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed innovative drug, HS-10510 tablets, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials targeting primary hypercholesterolemia and mixed dyslipidemia, potentially strengthening its position in the pharmaceutical industry and expanding its product offerings.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has announced its upcoming annual general meeting scheduled for June 20, 2025, in Hong Kong. Key agenda items include the adoption of the 2024 financial statements, approval of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks shareholder approval for mandates to repurchase shares and issue new shares, reflecting strategic moves to enhance shareholder value and operational flexibility.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group announced that its innovative drug Ameile (Aumolertinib Mesilate Tablets) has received approval from the National Medical Products Administration of China for a new indication. This approval allows Ameile to be used as an adjuvant treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific genetic mutations. This marks the fourth indication approval for Ameile, enhancing its market positioning and expanding its treatment options for NSCLC.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed B7-H4-targeted antibody-drug conjugate, HS-20089, has been granted Breakthrough-Therapy-Designated status by China’s National Medical Products Administration. This designation is for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The product is in Phase III clinical trials in China and has an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization outside Greater China, indicating significant potential for global market expansion.
Hansoh Pharmaceutical Group Company Limited has announced the grant of restricted share units (RSUs) under its Post-IPO RSU Scheme, involving 8,560,990 shares to 776 grantees, including one executive director and 775 employees. This move is part of the company’s strategy to incentivize its workforce, aligning their performance with the company’s goals, and potentially enhancing its market position by retaining key talent.
Hansoh Pharmaceutical Group Company Limited announced a final cash dividend of HKD 0.1353 per share for the financial year ending December 31, 2024. The dividend is subject to shareholders’ approval on June 20, 2025, and will be paid on July 25, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders, potentially strengthening its market position and investor confidence.
Hansoh Pharmaceutical Group Company Limited announced that its product, Hengmeida (Ibrexafungerp Tablets), has received drug registration approval from the National Medical Products Administration of China. This approval allows the company to market the drug for the treatment of vulvovaginal candidiasis in adult and post-menarche adolescent women, potentially enhancing its market position and expanding its product offerings in the pharmaceutical industry.
Hansoh Pharmaceutical Group Company Limited has announced that its self-developed B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough-Therapy-Designated status by the National Medical Products Administration of China for the treatment of non-squamous non-small cell lung cancer. This designation highlights the potential impact of HS-20093 on the company’s operations and industry positioning, as it progresses through multiple clinical trials, including Phase III, for various cancer treatments.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D mutations, have received Clinical Trial Approval from the National Medical Products Administration of China. This approval allows the company to proceed with clinical trials for advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, potentially enhancing its market position and offering new treatment options for these conditions.
Hansoh Pharmaceutical Group Company Limited has received approval from the National Medical Products Administration of China to conduct clinical trials for its self-developed drug, HS-20108, intended for the treatment of advanced solid tumors. This approval marks a significant step in the company’s efforts to enhance its product offerings in oncology, potentially strengthening its position in the pharmaceutical industry and providing new treatment options for patients with challenging cancer types.
Hansoh Pharmaceutical Group Company Limited announced that its antibody-drug conjugate, HS-20122 for injection, has received Clinical Trial Approval from the National Medical Products Administration of China. This approval allows the company to conduct clinical trials for advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer, potentially enhancing its position in the oncology market.